Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients

Background By comparing the detection rate and type of targeted gene mutations in non-small cell lung cancer (NSCLC) between amplification refractory mutation system PCR (ARMS-PCR) and next-generation sequencing (NGS), the characteristics and application advantages of non-small cell lung cancer dete...
Ausführliche Beschreibung

Background By comparing the detection rate and type of targeted gene mutations in non-small cell lung cancer (NSCLC) between amplification refractory mutation system PCR (ARMS-PCR) and next-generation sequencing (NGS), the characteristics and application advantages of non-small cell lung cancer detection are explained, providing a basis for clinicians to effectively select the corresponding detection methods. Methods and materials The cases of targeted genes for lung cancer were selected from the First Affiliated Hospital of Chongqing Medical University from January 2016 to October 2020. A sample of 4467 cases was selected, and they were diagnosed with NSCLC by Pathological biopsy. Sample sources include surgical resection, bronchoscope biopsy, metastatic biopsy, blood, sputum, cytology of pleural effusion. Among them, 3665 cases were detected by ARMS-PCR technique, and 802 cases were detected by NGS technology. The detection rate and type of ARMS-PCR and NGS techniques for EGFR gene mutations (including exon 18, exon 19, exon 20, exon 21 and so on) in different NSCLC samples were compared, respectively. Results The total mutation rate of EGFR gene detected by ARMS-PCR was 47.6% while 42.4% detected by NGS which indicated that there was a significant difference between the two methods in detecting total mutation of EGFR gene (P < 0.001). In different exons, the EGFR mutation rate detected by two methods is various. The mutation rate of exon 19 by ARMS-PCR detection was evidently higher than that of NGS detection, while the mutation rate of exons 20 and 21 by ARMS-PCR detection were statistically significantly lower than that of NGS detection. Moreover, the multiple mutation rate detected by NGS was 16.3% which was much higher than the 2.7% detected by ARMS-PCR with statistically different. Conclusion It showed that NGS could direct the drug use for the resistant patients. However, some rare loci could be detected by NGS but the importance and directed meaning are still unknown and the number of rare mutations is rare too. Further research on new biomarkers and technique is still needed for early diagnosis, directing drug use and assessing the therapy prognosis. Ausführliche Beschreibung

Autor*in:	He, Changlong [verfasserIn] Wei, Chengcheng Wen, Jun Chen, Shi Chen, Ling Wu, Yue Shen, Yifan Bai, Huili Zhang, Yangli Chen, Xueping Li, Xiaosong

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Non-small cell lung cancer (NSCLC) Amplification refractory mutation system PCR (ARMS-PCR) Next-generation sequencing (NGS) Epidermal growth factor receptor (EGFR) Mutation

Anmerkung:	© The Author(s) 2021

Übergeordnetes Werk:	Enthalten in: Journal of cancer research and clinical oncology - Berlin : Springer, 1904, 148(2021), 2 vom: 24. Okt., Seite 321-330
Übergeordnetes Werk:	volume:148 ; year:2021 ; number:2 ; day:24 ; month:10 ; pages:321-330

Links:	Volltext

DOI / URN:	10.1007/s00432-021-03818-w

Katalog-ID:	SPR046092676